|
|
Article: FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva.
- Article from:
- M2 Presswire
- Article date:
- February 20, 2009
CopyrightCOPYRIGHT 2009 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-20 February 2009-US Food and Drug Administration: FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva(C)1994-2009 M2 COMMUNICATIONS LTD
RDATE:19022009
The U.S. Food and Drug Administration today issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab). Three of those patients have died. All four patients were treated with the drug for more than three years. None of the patients were receiving other treatments that suppress the immune system.
The FDA is ...